MedTrace Logo

A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19

NCT05815498 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 13553

Last updated 2026-05-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-1283.222 versus mRNA-1273.222 (Part 1) and mRNA-1283.815 versus mRNA-1273.815 (Part 2).

Conditions

Interventions

BIOLOGICAL

mRNA-1283.222

Sterile liquid for injection

BIOLOGICAL

mRNA-1273.222

Sterile liquid for injection

BIOLOGICAL

mRNA-1283.815

Sterile liquid for injection

BIOLOGICAL

mRNA-1273.815

Sterile liquid for injection

Sponsors & Collaborators

  • ModernaTX, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-28
Primary Completion
2025-04-12
Completion
2025-04-12
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Japan
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05815498 on ClinicalTrials.gov